Brief: Immutep Says First Patient Dosed In Chemotherapy-Free Triple Combination Phase II Study
28/07/2023 16:23
July 28 (Reuters) - Immutep Ltd IMM.AX :
* FIRST PATIENT DOSED IN CHEMOTHERAPY-FREE TRIPLE
COMBINATION
PHASE II TRIAL TARGETING SOFT TISSUE SARCOMA
Source text for Eikon: ID:nGNX3hVpxx
Further company coverage: IMM.AX
((Reuters.Briefs@thomsonreuters.com;))